Peripheral T cells from patients with early systemic sclerosis kill autologous fibroblasts in co-culture: Is T-cell response aimed to play a protective role?

Rheumatology

Volumn 49, Issue 7, 2010, Pages 1257-1266

  de Palma, Raffaele ^a   D'aiuto, Elena ^a   Vettori, Serena ^a   Cuoppolo, PierPaolo ^a   Abbate, Gianfranco ^a   Valentini, Gabriele ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

Cytokines; Systemic sclerosis; T cell repertoires

Indexed keywords

FAS ANTIGEN; HLA DR ANTIGEN; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; TRANSFORMING GROWTH FACTOR BETA;

ADULT; ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; CD3+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CELL CULTURE; CELL EXPANSION; CELL GROWTH; CELL INFILTRATION; CLINICAL ARTICLE; COCULTURE; CONTROLLED STUDY; FEMALE; FIBROBLAST; HUMAN; HUMAN CELL; IMMUNE RESPONSE; LYMPHOCYTE FUNCTION; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PUNCH BIOPSY; REGULATORY MECHANISM; SKIN BIOPSY; SYSTEMIC SCLEROSIS; T LYMPHOCYTE; UPREGULATION;

ADULT; AGED; ANALYSIS OF VARIANCE; APOPTOSIS; BIOPSY; CELLS, CULTURED; COCULTURE TECHNIQUES; CYTOKINES; FEMALE; FIBROBLASTS; HUMANS; MALE; MIDDLE AGED; SCLERODERMA, SYSTEMIC; T-LYMPHOCYTES;

EID: 77954222254     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/keq094     Document Type: Article

References (41)

1. Medsger TA Jr. Systemic sclerosis (scleroderma): clinical aspects. In: WJ Koopman, ed. Arthritis and allied conditions, 14th edition. Philadelphia: Lippincott Williams & Wilkins, 2000:1590-624.
2. Varga J, Denton CP. Systemic sclerosis and the scleroderma-spectrum disorders. In: Firestein GS, Budd RC, Harris ED Jr, McInnes IB, Ruddy S, Sergent JS, eds. Kelley's textbook of rheumatology, 8th edition. Philadelphia: W.B. Saunders, 2009:1311-51.
3. Jimenez SA, Derk CT. Following the molecular pathways toward an understanding of the pathogenesis of systemic sclerosis. Ann Intern Med 2004;140:37-50.
4. Sakkas LI, Xu B, Artleth CM et al. Oligoclonal T cell expansion in the skin of patients with systemic sclerosis. J Immunol 2002;168:3649-59.
5. Gu YS, Kong J, Cheema GS et al. The immunobiology of systemic sclerosis. Semin Arthritis Rheum 2008;38: 132-60.
6. Mavalia C, Scaletti C, Romagnani P et al. Type 2 helper T-cell predominance and high CD30 expression in systemic sclerosis. Am J Pathol 1997;151:1751-8.
7. Chizzolini C. T cells, B cells, and polarized immune response in the pathogenesis of fibrosis and systemic sclerosis. Curr Opin Rheumatol 2008;20:707-12.
8. Valentini G, Romano MF, Naclerio C et al. Increased expression of CD40 ligand in activated CD4+ T lymphocytes of systemic sclerosis patients. J Autoimmun 2000;15:61-6.
9. Kalogerou A, Gelou E, Mountantonakis S et al. Early T-cell activation in the skin from patients with systemic sclerosis. Ann Rheum Dis 2005;64:1233-5.
10. Fukasawa C, Kawaguchi Y, Harigai M et al. Increased CD40 expression in skin fibroblasts from patients with systemic sclerosis (SSc): role of CD40-CD154 in the phenotype of SSc fibroblasts. Eur J Immunol 2003;33: 2792-800.
11. Tiev KP, Abriol J, Burland MC et al. T cell repertoire in patients with stable scleroderma. Clin Exp Immunol 2005; 139:348-54.
12. De Palma R, Del Galdo F, Lupoli S et al. Peripheral T lymphocytes from patients with early systemic sclerosis co-cultured with autologous fibroblasts undergo an oligoclonal expansion similar to that occurring in the skin. Clin Exp Immunol 2006;144:169-76.
13. Masi AT and Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980;23:581-90.
14. LeRoy EC, Black C, Fleischmajer R et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988;15:202-5.
15. Valentini G, Silman AJ, Veale D. Assessment of disease activity. Clin Exp Rheumatol 2003;21(Suppl. 29):s39-41.
16. Medsger TA Jr, Bombardieri S, Czirjak L et al. Assessment of disease severity and prognosis. Clin Exp Rheumatol 2003;21(Suppl. 29):s42-6.
17. Akesson A, Fiori G, Krieg T et al. Assessment of skin, joint, tendon and muscle involvement. Clin Exp Rheumatol 2003;21(Suppl. 29):s5-8.
18. Abraham D, Lupoli S, McWhirter A et al. Expression and function of surface antigens on scleroderma fibroblasts. Arthritis Rheum 1991;34:1164.
19. De Palma R, Gorski J. Restricted and conserved T-cell repertoires involved in allorecognition of class II major histocompatibility complex. Proc Natl Acad Sci USA 1995; 92:8836-40.
20. Pannetier C, Even J, Kourilsky P. T-cell repertoire diversity and clonal expansions in normal and clinical samples. Immunol Today 1995;16:176-81.
21. Bacsi S, De Palma R, Visentin GP et al. Complexes of heparin and platelet factor 4 specifically stimulate T cells from patients with heparin-induced thrombocytopenia/thrombosis. Blood 2001;94:208-15.
22. + T cell precursor. J Exp Med 2008;205: 1903-16.
23. Kleinschek MA, Boniface K, Sadekova S et al. Circulating and gut-resident human Th17 cells express CD161 and promote intestinal inflammation. J Exp Med 2009;206: 525-34.
24. Kawaguchi Y, Hara M, Wright TM. Endogenous IL-1a from systemic sclerosis fibroblasts induces IL-6 and PDGF-a. J Clin Invest 1999;103:1253-60.
25. Yamamoto T, Eckes B, Mauch C et al. Monocyte chemoattractant protein-1 enhances gene expression and synthesis of matrix metalloproteinase-1 in human fibroblasts byan autocrine IL-1b loop. J Immunol 2000; 164:6174-9.
26. Atamas SP, White B. Cytokine regulation of pulmonary fibrosis in scleroderma. Cytokine Growth Factor Rev 2003; 14:537-50.
27. McCormick LL, Zhang Y, Tootell E et al. Anti-TGF-b treatment prevents skin and lung fibrosis in murine sclerodermatous graft-versus-host disease: a model for human scleroderma. J Immunol 1999;163:5693-9.
28. Gruschwitz M, Muller PU, Sepp N et al. Transcription and expression of transforming growth factor type beta in the skin of progressive systemic sclerosis: a mediator of fibrosis? J Invest Dermatol 1990;94:197-203.
29. Atamas SP, White B. The role of chemokines in the pathogenesis of scleroderma. Curr Opin Rheumatol 2003; 15:772-7.
30. Sakkas LI, Chikanza IC, Platsoucas CD. Mechanisms of Disease: the role of immune cells in the pathogenesis of systemic sclerosis. Nat Clin Pract Rheumatol 2006;2: 679-85.
31. Yurovsky VV, Wigley FM, Wise RA et al. Skewing of the CD8+ T-cell repertoire in the lungs of patients with systemic sclerosis. Hum Immunol 1996;48: 84-97.
32. Liakouli V, Manetti M, Pacini A et al. The -670G>A polymorphism in the FAS gene promoter region influences the susceptibility to systemic sclerosis. Ann Rheum Dis 2009; 68:584-90.
33. Drappa J, Vaishnaw AK, Sullivan KE et al. Fas gene mutations in the Canale-Smith syndrome, an inherited lymphoproliferative disorder associated with autoimmunity. N Engl J Med 1996;335:1643-9.
34. Mahfoudh W, Bel Hadj Jrad B, Romdhane A et al. A polymorphism in FAS gene promoter correlated with circulating soluble FAS levels. Int J Immunogenet 2007;34: 209-12.
35. Bendersky A, Markovits N, Bank I. Vgamma9+ gammadelta T cells are numerically and functionally preserved and induce fibroblast apoptosis. Immunobiology. Advance Access published July 7, 2009, doi:10.1016/j.imbio.2009.05.012.
36. Chizzolini C, Parel Y, De Luca C et al. Systemic sclerosis Th2 cells inhibit collagen production by dermal fibroblasts via membrane-associated tumor necrosis factor a. Arthritis Rheum 2003;48:2593-604.
37. Chizzolini C, Rezzonico R, Ribbens C et al. Inhibition of type I collagen production by dermal fibroblasts upon contact with activated T-cells: different sensitivity to inhibition between systemic sclerosis and control fibroblasts. Arthritis Rheum 1998;41:2039-47.
38. Pearce SH, Merriman TR. Genetic progress towards the molecular basis of autoimmunity. Trends Mol Med 2006; 12:90-8.
39. Santarlasci V, Maggi L, Capone M et al. TGF-beta indirectly favors the development of human Th17 cells by inhibiting Th1 cells. Eur J Immunol 2009;39:207-15.
40. Deleuran B, Abraham DJ. Possible implication of the effector CD4+ T-cell subpopulation Th17 in the pathogenesis of systemic scleroderma. Nat Clin Pract Rheumatol 2007;3:682-3.
41. Murata M, Fujimoto M, Matsushita T et al. Clinical association of serum interleukin-17 levels in systemic sclerosis: is systemic sclerosis a Th17 disease? J Dermatol Sci 2008;50:240-2.